However, anti-PDL1 and anti-CTLA4 treatments have additive and synergistic effects on cancer treatment, based on the observation of the superior efficacy obtained by using the combination of CTLA4 blockade and PDL1 blockade in patients with melanoma compared with monotherapy (61). Here, CD274 is linked to cancer.